title: Targeted delivery of anti-inflammatory agents to tumors.
abstract: Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.
authors.affiliation: Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
authors.forename: Maria
authors.initials: M
authors.lastname: Coimbra
authors.forename: Sylvia A
authors.initials: SA
authors.lastname: Kuijpers
authors.forename: Sebastiaan P
authors.initials: SP
authors.lastname: van Seters
authors.forename: Gert
authors.initials: G
authors.lastname: Storm
authors.forename: Raymond M
authors.initials: RM
authors.lastname: Schiffelers
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators